Statement on the impact of coronavirus disease COVID-19 on our operations

Company news

The novel coronavirus disease Covid-19 first reported in Wuhan, China in late 2019 has spread far beyond China, and now affects approximately 200 countries.

At Fujirebio Europe’s Belgian facilities, we are taking steps to protect our employees, and encourage those who can do so to work from home.  The manufacture of medical products is considered an essential service in Belgium, and our production, quality, and logistics staff continue to work as before.  We have adequate inventories of raw materials to continue uninterrupted manufacturing operations of the INNO-LIA, INNO-LiPA, and INNOTEST product lines for many months. 

We do not foresee Serodia or Lumipulse manufacturing shortfalls from our Japanese operation resulting from Covid-19-related shutdowns.  However, the Covid-19 pandemic has resulted in unprecedented demand for lung, inflammation, and bacterial versus viral infection markers such as KL-6, IL-6, and PCT.  In response, the manufacturing site in Japan has scheduled additional production batches of these Lumipulse assays.  Please contact Order Handling for further details on product availability.

We continue to observe the impact of Covid-19 on air freight.  The cancellation of passenger flights that would normally also carry freight is limiting global air freight capacity. The result is that air freight is becoming progressively more complex and expensive.

Since our ability to ship product promptly by air is less certain than usual, we urge customers to anticipate their needs as far in advance as possible to better facilitate on-time delivery.

We wish all of our customers and their families good health during this unusual and  challenging time.


Christiaan De Wilde
On behalf of CDW Invest BV